TC
AMRI

TFS Capital’s Albany Molecular Research Inc AMRI Stock Holding History

TFS Capital’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-101,698
Closed -$2.02M – 1189
2015
Q4 		$2.02M Buy
+101,698
New +$1.93M 0.22% 161
2014
Q2 		– Sell
-28,045
Closed -$521K – 1508
2014
Q1 		$521K Buy
28,045
+14,144
+102% +$195K 0.03% 714
2013
Q4 		$140K Sell
13,901
-299,618
-96% -$3.62M 0.01% 1353
2013
Q3 		$4.04M Sell
313,519
-177,119
-36% -$2.18M 0.18% 137
2013
Q2 		$5.82M Buy
+490,638
New +$5.32M 0.24% 72

Other funds holding AMRI

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TFS Capital's AMRI Position: Q1 2016 in Review

TFS Capital sold out of Albany Molecular Research Inc (AMRI) in Q1 2016, closing a stake of 101,698 shares — an estimated $2.02M sold.

TFS Capital first reported a position in AMRI in Q2 2013 and held it in 5 quarters. The position peaked at $5.82M in Q2 2013. 141 funds tracked by Wall St. Rank hold AMRI as of Q1 2016.

  • TFS Capital reported no remaining Albany Molecular Research Inc position as of Q1 2016 after selling out during the quarter.
  • TFS Capital sold 101,698 Albany Molecular Research Inc shares in Q1 2016, an estimated $2.02M.
  • TFS Capital first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 5 quarters.
  • TFS Capital's Albany Molecular Research Inc position peaked at $5.82M in Q2 2013.
  • 141 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2016.

Based on TFS Capital's 13F filing for Q1 2016, filed 10 May 2016.